Skip to main content
News.
Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery
July 1, 2025

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery

Study identifies new metrics to enhance scRNA-seq based virtual cell modelling Foundational paper to drive development of improved virtual cell models for rejuvenation target discovery…
Read More
Shift Bioscience identifies novel single-gene target for safer cellular rejuvenation therapeutics
June 9, 2025

Shift Bioscience identifies novel single-gene target for safer cellular rejuvenation therapeutics

SB000 reverses cellular ageing as measured by DNA methylation clocks in multiple cell types without loss of cellular identity or signs of pluripotency Study advances…
Read More
Shift Bioscience appoints Lord David Prior and Sir Tony Kouzarides to support long-term strategy for cell rejuvenation therapeutics
May 20, 2025

Shift Bioscience appoints Lord David Prior and Sir Tony Kouzarides to support long-term strategy for cell rejuvenation therapeutics

Lord David Prior appointed as Chair of the Board, previously Chairman of NHS England and member of the UK Life Sciences Council Sir Tony Kouzarides,…
Read More
Shift Bioscience announces key appointments to advance rejuvenation therapeutics pipeline
March 13, 2025

Shift Bioscience announces key appointments to advance rejuvenation therapeutics pipeline

Jill Reckless (CEO, RxCelerate) appointed as Translation Advisor Laurence Reid joins as Non-Executive Director, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Millennium Pharmaceuticals Cambridge,…
Read More
Shift Bioscience establishes North American facilities to expand capabilities of AI-powered virtual cell technology
February 18, 2025

Shift Bioscience establishes North American facilities to expand capabilities of AI-powered virtual cell technology

Head of Machine Learning, Lucas Camillo (centre right) to lead team with Professor Bo Wang, University of Toronto (centre) appointed as Senior Advisor Expansion into…
Read More
Daniel Ives talks to AWS about the AI virtual cell and its key role in discovery of rejuvenation biology
December 17, 2024

Daniel Ives talks to AWS about the AI virtual cell and its key role in discovery of rejuvenation biology

#112 Defeating the Diseases of Aging with Daniel Ives from Shift Bioscience About Shift Bioscience Shift Bioscience is a biotech company uncovering the biology of…
Read More
Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery
July 1, 2025

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery

Study identifies new metrics to enhance scRNA-seq based virtual cell modelling Foundational paper to drive development of improved virtual cell models for rejuvenation target discovery…
Read More
Shift Bioscience identifies novel single-gene target for safer cellular rejuvenation therapeutics
June 9, 2025

Shift Bioscience identifies novel single-gene target for safer cellular rejuvenation therapeutics

SB000 reverses cellular ageing as measured by DNA methylation clocks in multiple cell types without loss of cellular identity or signs of pluripotency Study advances…
Read More
Shift Bioscience appoints Lord David Prior and Sir Tony Kouzarides to support long-term strategy for cell rejuvenation therapeutics
May 20, 2025

Shift Bioscience appoints Lord David Prior and Sir Tony Kouzarides to support long-term strategy for cell rejuvenation therapeutics

Lord David Prior appointed as Chair of the Board, previously Chairman of NHS England and member of the UK Life Sciences Council Sir Tony Kouzarides,…
Read More
Shift Bioscience announces key appointments to advance rejuvenation therapeutics pipeline
March 13, 2025

Shift Bioscience announces key appointments to advance rejuvenation therapeutics pipeline

Jill Reckless (CEO, RxCelerate) appointed as Translation Advisor Laurence Reid joins as Non-Executive Director, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Millennium Pharmaceuticals Cambridge,…
Read More
Shift Bioscience establishes North American facilities to expand capabilities of AI-powered virtual cell technology
February 18, 2025

Shift Bioscience establishes North American facilities to expand capabilities of AI-powered virtual cell technology

Head of Machine Learning, Lucas Camillo (centre right) to lead team with Professor Bo Wang, University of Toronto (centre) appointed as Senior Advisor Expansion into…
Read More
Lucas Camillo and Bo Wang release CpGPT, a foundation model for DNA methylation
October 30, 2024

Lucas Camillo and Bo Wang release CpGPT, a foundation model for DNA methylation

Shift Bioscience Head of ML Lucas Camillo and advisor Bo Wang released CpGPT, a foundation model for DNA methylation. Lucas used a fine-tuned CpGPT to…
Read More
Shift Bioscience raises $16M to advance AI virtual cell platform for cell rejuvenation
October 15, 2024

Shift Bioscience raises $16M to advance AI virtual cell platform for cell rejuvenation

Investment led by BGF, with support from existing investors F-Prime Capital, Kindred Capital, and Jonathan Milner Seed funding will accelerate development of Shift Bioscience’s platform…
Read More
Shift Bioscience at the Investing in the Age of Longevity Conference 2021
November 2, 2021

Shift Bioscience at the Investing in the Age of Longevity Conference 2021

The Path to Safe Cellular Rejuvenation Investing in the Age of Longevity 2021  |  Daniel Ives  |  Shift Bioscience | Shift Bioscience presenting at the…
Read More
Daniel Ives talks to AWS about the AI virtual cell and its key role in discovery of rejuvenation biology
December 17, 2024

Daniel Ives talks to AWS about the AI virtual cell and its key role in discovery of rejuvenation biology

#112 Defeating the Diseases of Aging with Daniel Ives from Shift Bioscience About Shift Bioscience Shift Bioscience is a biotech company uncovering the biology of…
Read More
Guardian article on rejuvenation race mentions Shift Bioscience
November 5, 2023

Guardian article on rejuvenation race mentions Shift Bioscience

British biotech races US’s ‘buff billionaires’ for secret of eternal youth An article in the Guardian on rejuvenation race has mentioned Shift Bioscience. Read on…
Read More
Daniel Ives features in Cambridge University’s Enterprising Minds
July 20, 2022

Daniel Ives features in Cambridge University’s Enterprising Minds

Live Long and Prosper Shift Bioscience's Daniel Ives features in Cambridge University's Enterprising Minds. Find out more on the Cambridge University website. About Shift Bioscience…
Read More
Daniel Ives interviewed by Eleanor Sheekey
February 10, 2022

Daniel Ives interviewed by Eleanor Sheekey

Inside a Longevity Biotech Company - Shift Bioscience About Shift Bioscience Shift Bioscience is a biotech company uncovering the biology of cell rejuvenation to develop…
Read More
Nature Biotechnology features Shift Bioscience
January 25, 2022

Nature Biotechnology features Shift Bioscience

Rejuvenation by controlled reprogramming is the latest gambit in anti-aging Nature Biotechnology features Shift Bioscience. Read the article on Nature.com About Shift Bioscience Shift Bioscience…
Read More
FT features Shift Bioscience in The Weekend Essay
October 6, 2021

FT features Shift Bioscience in The Weekend Essay

Can we defeat death? FT features Shift Bioscience in The Weekend Essay. Read the article on FT.com (subscription required). About Shift Bioscience Shift Bioscience is…
Read More
Daniel Ives presents to the Foresight Biotech & Health extension
July 15, 2021

Daniel Ives presents to the Foresight Biotech & Health extension

Drug Target Discovery for Cellular Rejuvenation by ‘Driver’ Clocks Daniel Ives presents to the Foresight Biotech & Health extension About Shift Bioscience Shift Bioscience is…
Read More
CEO Daniel Ives discusses Shift Bioscience on BioInnovation Spotlight
July 8, 2021

CEO Daniel Ives discusses Shift Bioscience on BioInnovation Spotlight

Reversing Ageing with Daniel Ives of Shift Bioscience CEO Daniel Ives discusses Shift Bioscience on BioInnovation Spotlight. Listen to the content at BioInnovation Spotlight. About…
Read More
Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery
July 1, 2025

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery

Study identifies new metrics to enhance scRNA-seq based virtual cell modelling Foundational paper to drive development of improved virtual cell models for rejuvenation target discovery…
Read More
Shift Bioscience identifies novel single-gene target for safer cellular rejuvenation therapeutics
June 9, 2025

Shift Bioscience identifies novel single-gene target for safer cellular rejuvenation therapeutics

SB000 reverses cellular ageing as measured by DNA methylation clocks in multiple cell types without loss of cellular identity or signs of pluripotency Study advances…
Read More
Lucas Camillo and Bo Wang release CpGPT, a foundation model for DNA methylation
October 30, 2024

Lucas Camillo and Bo Wang release CpGPT, a foundation model for DNA methylation

Shift Bioscience Head of ML Lucas Camillo and advisor Bo Wang released CpGPT, a foundation model for DNA methylation. Lucas used a fine-tuned CpGPT to…
Read More